Please note that following on from information provided to NICE by the company in May 2014, the appraisal of Tolevamer for clostridium difficile associated diarrhoea [ID378] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 378 |
| Referral date | 01 June 2007 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Assessment Group / Evidence Review Group: | TBC |
| Communications manager: | TBC |
| Executive Lead: | Gillian Leng |
| Project manager: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in May 2014, the appraisal of Tolevamer for clostridium difficile associated diarrhoea [ID378] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 14 May 2014 |
As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of tolevamer for clostridium difficile.. Following an update on the regulatory status of this technology, the manufacturer has informed us that development on tolevamer for clostridium difficile has stopped and there are no plans to seek regulatory approval. Therefore, the appraisal remains suspended. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual